Moon Shinje, Kong Sung Hye, Choi Hoon Sung, Hwangbo Yul, Lee Moon-Kyu, Moon Jae Hoon, Jang Hak Chul, Cho Nam Han, Park Young Joo
Department of Internal Medicine, Hallym University College of Medicine, Seoul, Republic of Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Am J Cardiol. 2018 Aug 15;122(4):571-577. doi: 10.1016/j.amjcard.2018.03.371. Epub 2018 May 16.
The aim of this study was to determine the association between subclinical hypothyroidism and cardiovascular (CVD) events, and mortality using the atherosclerotic CVD risk score. We carried out an observational study in a prospective cohort that was followed up for 12 years. The study included 3,021 participants aged ≥ 40 years at baseline from the Ansung cohort, part of the Korean Genome and Epidemiology Study. Cox regression models were constructed to evaluate the hazards ratio (HR) and 95% confidence interval (CI) for all-cause mortality and CVD events in groups classified according to thyroid status. Subgroup analysis was performed with a cut-off age of 65 years or 7.5% of the 10-year atherosclerotic CVD risk score. The subclinical hypothyroidism group in the highest quartile of thyroid-stimulating hormone (>6.57 mIU/L) had a significantly increased risk of all-cause mortality (HR 2.12, 95% CI 1.27 to 3.56) and CVD events (HR 1.92, 95% CI 1.21 to 3.04) compared with euthyroid participants. Subgroup analysis by CVD risk revealed that participants with high CVD risk only had a high risk of all-cause mortality (HR 2.18, 95% CI 1.22 to 3.87) and CVD events (HR 2.42, 95% CI 1.35 to 4.33). Further analysis showed that participants aged <65 years with high CVD risk had the highest risk of all-cause mortality (HR 3.50, 95% CI 1.50 to 8.16) and CVD events (HR 3.37, 95% CI 1.46 to 9.57). Our results demonstrated that high thyroid-stimulating hormone levels were associated with a greater risk of mortality and new CVD risks, particularly among subjects with high CVD risk.
本研究旨在使用动脉粥样硬化性心血管疾病(CVD)风险评分来确定亚临床甲状腺功能减退与心血管(CVD)事件及死亡率之间的关联。我们在一个前瞻性队列中进行了一项观察性研究,随访时间为12年。该研究纳入了来自韩国基因组与流行病学研究一部分的安城队列中3021名基线年龄≥40岁的参与者。构建Cox回归模型以评估根据甲状腺状态分类的各组全因死亡率和CVD事件的风险比(HR)及95%置信区间(CI)。采用65岁的年龄切点或10年动脉粥样硬化性CVD风险评分的7.5%进行亚组分析。促甲状腺激素最高四分位数(>6.57 mIU/L)的亚临床甲状腺功能减退组与甲状腺功能正常的参与者相比,全因死亡率(HR 2.12,95% CI 1.27至3.56)和CVD事件(HR 1.92,95% CI 1.21至3.04)的风险显著增加。按CVD风险进行的亚组分析显示,CVD风险高的参与者仅全因死亡率(HR 2.18,95% CI 1.22至3.87)和CVD事件(HR 2.42,95% CI 1.35至4.33)的风险高。进一步分析表明,CVD风险高且年龄<65岁的参与者全因死亡率(HR 3.50,95% CI 1.50至8.16)和CVD事件(HR 3.37,95% CI 1.46至9.57)的风险最高。我们的结果表明,促甲状腺激素水平高与更高的死亡风险和新的CVD风险相关,特别是在CVD风险高的受试者中。